Type I interferons and the Th1/Th2 paradigm. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Type I interferons and the Th1/Th2 paradigm.

Dev Comp Immunol. 1999 Oct-Dec;23(7-8):657-63. Unique Identifier : AIDSLINE MED/20043995
Sinigaglia F; D'Ambrosio D; Rogge L; Roche Milano Ricerche, Italy. francesco.sinigaglia@roche.com

Abstract: During the past year significant advances have been made in our understanding of the factors contributing to the differentiation of CD4+ T helper cell subsets. These have been driven, in part, by the realization that cytokines from the innate immune response, such as interleukin-12 (IL-12) and interferons (IFNs), play a critical role in T cell subset differentiation. This review covers some of the most recent data concerning the divergent role that IFNs have in the differentiation of human versus mouse T helper cell subsets. In this review we discuss the molecular basis for the specie-specific effect of type I IFN on the selective induction of Th1 type immune responses. Furthermore, since IFN-beta is used in the treatment of multiple sclerosis (MS) we discuss the potential effects of such treatment and the value of the Th1/Th2 paradigm in MS.
Keywords: JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL Animal Cell Division DNA-Binding Proteins/IMMUNOLOGY Human Interferon Type I/*IMMUNOLOGY Interleukin-12/IMMUNOLOGY Mice Multiple Sclerosis/DRUG THERAPY/IMMUNOLOGY Species Specificity Th1 Cells/CYTOLOGY/*IMMUNOLOGY Th2 Cells/CYTOLOGY/*IMMUNOLOGY Trans-Activators/IMMUNOLOGYKWDjournalarticlereviewreview,tutorialanimalcelldivisiondna-bindingproteins/immunologyhumaninterferontypei/KWDimmunologyinterleukin-12/immunologymicemultiplesclerosis/drugtherapy/immunologyspeciesspecificityth1cells/cytology/KWDimmunologyth2cells/cytology/KWDimmunologytrans-activators/immunology
000530
A0051892

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .